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The CD28 Costimulatory Domain Enhances Antigen-Specific
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T cells require both primary and costimulatory signals for optimal activation. The primary Ag-specific signal is delivered by
engagement of the TCR. The second Ag-independent costimulatory signal is mediated by engagement of the T cell surface
costimulatory molecule CD28 with its target cell ligand B7. However, many tumor cells do not express these costimulatory
molecules. We previously constructed phage display derived FAB, G8, and Hyb3, Ab-based receptors with identical specificity but
distinct affinities for HLA-A1/MAGE-A1, i.e., “TCR-like” specificity. These chimeric receptors comprised the FcRI- signaling
element. We analyzed whether linking the CD28 costimulation structure to it (  CD28) could affect the levels of MHC-restricted
cytolysis and/or cytokine production. Human scFv-G8POS T lymphocytes comprising the   CD28 vs the  signaling element
alone produced substantially more IL-2, TNF-, and IFN- in response to HLA-A1/MAGE-A1POS melanoma cells. Also a drastic
increase in cytolytic capacity of scFv-G8POS T cells, equipped with   CD28 vs the -chain alone was observed. The Journal
of Immunology, 2005, 174: 7853–7858.
T umor-associated Ags (1) or MHC class I-presented tumorrejection Ags (TRA)3 (2, 3) can be targeted by CTL-ex-pressing (chimeric) single chain (sc) or two chain mAbs
(4–10) or TCR (11–16), respectively. Most immunotherapeutic
strategies targeting TRA aim to induce and enhance the number of
tumor-specific T lymphocytes in patients by peptide vaccination,
because such cells can have the capacity to lyse (native) tumor
cells (17, 18), and the transfer of such tumor-specific T lympho-
cytes to patients can have clinical significance (19–22). However,
the isolation of tumor-specific CTL and their expansion to signif-
icant numbers for clinical application on an individual basis is
cumbersome and the outcome unpredictable.
We and others developed strategies to permanently graft pri-
mary human T lymphocytes with MHC-restricted tumor specificity
via retroviral introduction of, e.g., chimeric or nonmodified TCR
 genes (11–16) or mAb-based receptors (23, 24). Engineered
primary human T lymphocytes expressing (chimeric) TCRs or two
chain TCR-like mAbs display the Ag specificity dictated by the
introduced TCR or TCR-like mAb; i.e., they specifically lyse rel-
evant tumor cells and produce cytokines. To become independent
of the availability of host-derived or in vitro stimulated tumor-
specific CTL (clones) as a source of TCR  genes but still target
TRA, we generated phage display-derived human mAbs with
MHC-restricted TCR-like Ag specificities to genetically retarget
human T cells to their tumors (23, 24). TCR as well as TCR-like
Abs clearly differ from classical Abs not only with respect to their
MHC restriction of Ag recognition but also with regard to ligand
binding affinity, which is generally at least a log phase higher for
classical mAb vs TCR-like Abs. We took advantage of the relative
ease to adopt phage display libraries to allow for in vitro affinity
maturation of these peptide/MHC-specific mAbs. Indeed, affinity
maturation of the HLA-A1/MAGE-A1-specific Fab G8 resulted in
a hyb3 variant, which displayed an 18-fold higher ligand binding
affinity (24). Primary human T lymphocytes expressing this affin-
ity-matured chimeric two chain Fab receptor showed enhanced in
vitro immune functions, i.e., showed significantly higher levels of
Ag-triggered production of TNF-, IFN-, and IL-2, but also tu-
mor cell lysis (24). Here we explored whether specific immune
responses of T cells expressing chimeric single chain TCR-like
(scFv) receptors could be further enhanced by linking the CD28
costimulatory domain to the -chain signaling element in both low
and high affinity TCR-like scFvPOS T lymphocytes. To this end,
we used scFv rather than two chain TCR-like receptor genes be-
cause this approach allows the introduction of scFv vs two chain
TCR-like genes with higher efficiency. Primary human T lympho-
cytes with CD28   signaling elements vs  alone showed a
significantly enhanced specific anti-tumor response, also at low
TRA densities on tumor cells, and produce higher levels of the
TNF-, IFN-, and IL-2 cytokines.
Materials and Methods
Cells and antibodies
T lymphocytes derived from healthy donors were isolated and expanded as
described (25). Target cell lines used in this study are: 1) the native
MAGE-A1POS, HLA-A1POS melanoma cell line MZ2-MEL 3.0 (MEL3.0);
2) the MAGE-A1NEG, HLA-A1POS melanoma cell line MZ2-MEL 2.2
(MEL2.2) (kindly provided by T. Boon and P. Coulie, Ludwig Center
Research Center, Brussels, Belgium) (26); 3) the HLA-A1POS B-LCL
APD; and 4) the erythroid leukemia cell line K562. The human embryonic
kidney cell line 293T (27) (kindly provided by Y. Soneoka, Department of
Biochemistry, Oxford University, Oxford, U.K.,) and phoenix-amph (28)
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(kindly provided by G. Nolan, Department of Microbiology and Immunol-
ogy, School of Medicine, Stanford University, Stanford, CA) were used as
packaging cell lines for the pBullet scFv- and scFv-  CD28 retroviral
vectors. Abs that were used in this study were anti-CD3 mAb OKT3 (Ortho
Diagnostics) and anti-CD28 (CLB Amsterdam).
Construct synthesis and retroviral gene transfer
Constructs containing chimeric receptors (Fig. 1) were generated in two
steps. First, the genes encoding the Fab G8 or Hyb3 H and L chain frag-
ments (23, 24) were subjected to PCR to introduce restriction sites that
allow gene insertion into the pBlue-212 vector (12). Second, the scFv G8
and scFv Hyb3 were introduced into the pBullet retroviral vector (12),
either 5 to a   CD28 fragment, which was derived from the scFv-
SP6  CD28 construct (29), or 5 to a fragment comprising the CD4
transmembrane domain and the intracellular domain of FcRI- (23) re-
sulting in the low affinity receptor vectors pBullet scFvG8-  CD28 and
pBullet scFvG8-, and the high affinity receptor vectors pBullet
scFvHyb3-  CD28, pBullet scFvHyb3-, respectively.
These low and high affinity scFv receptor genes were introduced into
OKT3-activated primary human T lymphocytes by retronectin-enhanced
supernatant transduction, essentially as described (23). Chimeric receptor-
expressing T cells were then expanded in medium supplemented with
rIL-2 (30).
Flow cytometry and enrichment of receptor-expressing T cells
To assess the expression of low and high affinity scFv-  CD28 and
scFv- receptors on gene-transduced primary human T lymphocytes, 0.5
106 cells were stained for 30 min at 4°C with saturating concentrations (11
nM final) of PE-labeled HLA-A1/MAGE-A1 tetramers, as described (12).
The dot plots show viable T lymphoblast gated on forward (FSC) and
sideward (SSC) light scatter signals. Analysis was performed on a FAC-
Scan instrument (BD Biosciences). To enrich for chimeric receptor-ex-
pressing T lymphocytes, transduced T lymphocytes were first incubated
with PE-labeled HLA-A1/MAGE-A1 tetramers, followed by anti-
PE-coated magnetic beads. Tetramer-binding T cells were subsequently
obtained by magnetic separation using Miltenyi miniMacs columns (Milte-
nyi Biotec) according to the manufacturer’s instructions. Recombinant IL-2
(10 IU/ml) was present during the entire enrichment procedure.
Cytotoxicity assays
Cytolytic activities of enriched low and high affinity scFv-  CD28 or
scFv--transduced human T lymphocytes were measured in 51Cr release
assays at indicated times, as described elsewhere (12). Peptide loading of
target cells was performed by addition of MAGE-A1 nonapeptide
(EADPTGHSY; Leiden University Medical Center, Leiden, The Nether-
lands) or an irrelevant influenza peptide derived from influenza virus A
nucleoprotein (CTELKLSDY; Leiden University Medical Center) to target
cells 5–15 min before incubation with effector T lymphocytes. The per-
centage of specific 51Cr release was calculated as follows: ((test counts 
spontaneous counts)/(maximum counts  spontaneous counts))  100%.
Experiments were performed in triplicate, and the SD did not exceed 10%.
TNF-, IFN-, and IL-2 ELISA
To quantify secreted TNF-, IFN-, and IL-2, transduced and enriched
human T lymphocytes (6  104) were cultured for 24 h either in the
presence or absence of 2  104 adherent tumor cells. When TNF- and
IFN- production was assessed, culture medium was supplemented with
360 IU/ml rIL-2, whereas IL-2 production was assessed in medium without
exogenous IL-2. Supernatants were harvested and levels of TNF-, IFN-,
and IL-2 were measured by standard ELISA according to the manufactur-
er’s instructions (CLB Amsterdam). Experiments were performed in trip-
licate, and the SD did not exceed 10%. The t test for means was used to
analyze ELISA results.
Results
ScFvG8 (low affinity) and scFvHyb3 (high affinity) comprising
either   CD28 or  signaling elements can be functionally
expressed on primary human T lymphocytes
Genes encoding the chimeric receptors scFvG8-  CD28,
scFvG8-, scFvHyb3-  CD28, and scFvHyb3-, specific for
HLA-A1/MAGE-A1, were retrovirally introduced into OKT3-ac-
tivated PBL (Fig. 1). Cell surface expression of the chimeric low
affinity scFvG8-  CD28 and scFvG8- on the one hand and
high affinity scFvHyb3-  CD28 and scFvHyb3- TCR-like re-
ceptors on the other was demonstrated by PE-labeled HLA-A1/
MAGE-A1 tetramer staining. Over 45% of enriched T cell trans-
ductants specifically bound the MAGE-A1/HLA-A1 tetramers
(Fig. 2A). Expression of the endogenous CD28 coreceptor on anti-
CD3-activated gene-transduced T lymphocytes was lacking (Fig.
2B), as reported for specific Ag-activated T lymphocytes (31).
FIGURE 1. Schematic presentation of the low and high affinity
scFvG8-, Hyb3- and scFvG8-  CD28, Hyb3-  CD28 constructs.
VH, variable heavy domain; l, linker; VL, variable L chain domain; CD4
Tm, CD4 transmembrane domain amino acids 395–419; CD28, CD28
amino acids 135–215; , FcRI- amino acids 45–88.
FIGURE 2. A, Low affinity scFvG8-, scFvG8- CD28, and high affinity
scFvHyb3-, scFvHyb3-CD28 transduced primary human T lymphocytes
specifically bind HLA-A1/MAGE-A1 tetramers. Cell surface expression of the
scFv- and scFv-  CD28 receptors on transduced and tetramer-enriched T
lymphocytes was analyzed via HLA-A1/MAGE-A1 tetramer staining (A1/
M1; filled histogram). As a control for specific binding, HLA-A1/Flu tetramers
were used, which contain a peptide derived from influenza nucleoprotein A
(A1/Flu; open histogram). B, Absence of CD28 expression on OKT-3 mAb-
activated T lymphocytes. Results are shown as histograms. Data acquisition
was restricted to viable cells.
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ScFvG8-  CD28POS T lymphocytes produce higher amounts
of TNF-, IFN-, and IL-2 in response to melanoma target cells
than scFvG8-POS T lymphocytes
TNF-, IFN-, and IL-2 production by scFvG8- CD28POS and
scFvG8-POS T lymphocytes was measured following 24 h of in-
cubation with stimulator cells: 1) native HLA-A1POS/MAGE-
A1POS melanoma cell line MEL3.0; 2) MAGE-A1 peptide-loaded
melanoma cell line MEL2.2; and 3) HLA-A1POS/MAGE-A1NEG
MEL2.2 melanoma cells. The low affinity CD28  POS T cell
transductants showed increased and specific cytokine production
in response to MAGE-A1POS melanoma cells in comparison with
POS T lymphocytes. High affinity CD28  POS T cell transduc-
tants also showed higher cytokine production levels in response to
MAGE-A1POS melanoma cells, but this enhanced cytokine re-
sponse was in part nonspecific because MAGE-A1NEG Ag lost
mutant melanoma cells triggered IFN- and TNF- production,
but again production in response to MAGE-A1POS melanoma cells
was still higher (Fig. 3B). Control MAGE-A1NEG target cells that
were loaded with an irrelevant peptide did not induce cytokine
production by scFvG8-  CD28POS, scFvG8-POS and
scFvHyb3-POS T lymphocytes (data not shown).
scFv-  CD28POS CTL mediate higher levels of MAGE-A1POS
melanoma cell lysis than scFv-POS CTL
The cytotoxic responses of scFvG8-  CD28POS; scFvG8-POS;
scFvHyb3-  CD28POS, and scFvHyb3-POS T lymphocytes
were measured following a 4-h incubation with 51Cr-labeled target
cells: 1) HLA-A1POS/MAGE-A1POS MEL3.0 melanoma cells; 2)
MAGE-A1 peptide loaded MEL2.2 melanoma cells; 3) HLA-
A1POS/MAGE-A1NEG MEL2.2 cells; 4) control HLA-A1POS B-
LCL APD; and 5) control K562 myeloid leukemia cells. Sig-
nificant higher levels of specific cytolysis were obtained when
HLA-A1POS/MAGE-A1POS melanoma cells and MAGE-A1-pep-
tidePOS melanoma target cells were incubated with low affinity
scFvG8-  CD28POS T lymphocytes when compared with
scFvG8-POS T lymphocytes (Fig. 4A).
Remarkably, significant higher levels of specific target cell lysis
by high affinity scFvHyb3-  CD28POS T lymphocytes were ob-
served, not only of relevant HLA-A1POS/MAGE-A1POS mela-
noma cells, but also of irrelevant K562 and APD target cells, as
well as MAGE-A1NEG Ag lost mutant melanoma cells (Fig. 4B).
When MAGE-A1NEG Ag lost mutant MZ2-MEL2.2 melanoma
target cells were loaded with increasing concentrations of
MAGE-A1 peptide (ranging from 1 nM to 10 M) and used as
specific target cells, the low affinity scFvG8-  CD28POS vs
scFvG8-POS T lymphocytes showed a significant increased spe-
cific lytic capacity. ScFvG8-CD28  POS vs scFvG8-POS T
lymphocytes required 10-fold less MAGE-A1 Ag at the target cell
than scFvG8-POS T lymphocytes for triggering of equal levels of
Ag-specific cytolytic activity (Fig. 4C). High affinity CD28 
POS T cells also demonstrated enhanced cytolytic activity when
compared with the Hyb3-POS T cells, but this enhanced cytolytic
activity was only partial specific as non-MAGE-A1 peptide loaded
target cells were also lysed (Fig. 4C).
Discussion
We have in vitro generated class I-HLA-A1/MAGE-A1-specific
human CTLs by genetically programming primary human T lym-
phocytes with low affinity G8 and high affinity Hyb3 receptors
comprising the -chain signaling element (23, 24). These phage
display-derived G8 and Hyb3 receptors display a TCR-like spec-
ificity, i.e., they recognize MAGE-A1 in the context of class I-
HLA-A1. Here we describe the immune response enhancing ef-
fects of genetically linking the CD28 costimulation structure to the
-chain in low and high affinity receptors (G8 and Hyb3 mAbs,
respectively). This was done because first, human tumor cells re-
portedly lack the B7 ligand for CD28 (32); second, we discovered
that virtually all human T lymphocytes lack functional expression
of the critical costimulatory CD28 molecule following T lympho-
cyte activation in vitro by anti-CD3 mAb (OKT3), which is re-
quired for subsequent gene transduction; third, classic scFv mAb-
based receptorPOS T lymphocytes, i.e., with MHC nonrestricted
FIGURE 3. Tumor-specific TNF-,
IFN-, and IL-2 production by enriched
low affinity scFvG8-  CD28POS and
scFvG8-POS T lymphocytes (A), and
high affinity scFvHyb3-  CD28POS
and scFvG8-POS T lymphocytes (B).
Transduced T lymphocytes were cul-
tured for 24 h in the presence of the fol-
lowing tumor cells: 1) M-1, MEL2.2;
2) native M-1, MEL3.0; and 3) M-1P,
MEL2.2  MAGE-A1 peptide (10
g/ml final). After 24 h, levels of
TNF-, IFN-, and IL-2 present in the
supernatant were measured by standard
ELISA. Shown are mean percentages of
specific cytokine release of triplicate
measurements, with SDs not exceeding
10% of mean values. Results from one
representative experiment of three are
shown. p values (low affinity p 0.001/
high affinity p  0.002) for a–f were
obtained with Student’s t test.
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Ag recognition, comprising  or   CD28 signaling structures
show significant enhanced cytokine production but no enhanced
cytolytic capacity (33–44).
The immune responses of phage display-derived Ab receptorPOS
CTLs with TCR-like specificity comprising the combined  
CD28 signaling elements were significantly enhanced, not only at
the level of cytokine production triggered by TRAPOS stimulator
cells, but surprisingly also at the level of TRA-specific target cell
lysis. In contrast, human T lymphocyte transductants expressing
classic scFv mAb-based receptors comprising   CD28 or  only
showed increased cytokine production capacity but no increased
lytic capacity (37, 42, 44). The immune responses of these low and
high affinity receptorPOS T cell transductants with the   CD28
signaling element, which lack functional expression of CD28
themselves, are efficiently reconstituted by incorporation of the
CD28 costimulatory element into the scFv- receptor. Because the
CD28 costimulatory element is now built into the scFv- receptor
the frequent lack of the B7 ligand expression on tumor cells is
bypassed. T lymphocytes expressing low affinity scFvG8 compris-
ing the combined   CD28 signaling element display significant
enhanced production of TNF-, IFN-, and IL-2 in response to
relevant MAGE-A1POS stimulator cells. The enhanced cytokine
production levels may also have relevant consequences in adoptive
immunogene therapy because it has been reported that classic
MHC nonrestricted scFv Ab-based receptorPOS T cell transduc-
tants comprising   CD28 or   CD28 provided animals with
increased reduction of tumor mass that appeared IFN- dependent
(35, 36, 38). The tumor-specific induction of, e.g., IL-2 production
by scFvG8-  CD28POS T lymphocytes may bypass the need for
exogenous IL-2 in clinical trials to obtain enhanced anti-tumor
activity as well as prolonged life span (21, 22, 45). Reportedly, the
life span of human CMV-reactive CTL and adoptively transferred
MART1/MelanA or gp100-specific T cell clones was indeed pro-
longed by the administration of exogenous IL-2 (21, 45).
The level of immune responses of low affinity scFvG8- 
CD28POS T lymphocytes was comparable to that of high affinity
scFv Hyb3- alone receptorPOS T lymphocytes and was HLA-A1/
MAGE-A1 specific. However, when the high affinity receptor was
engineered to comprise the combined   CD28, we discovered
that they also were triggered by, i.e., nonspecific MAGE-A1NEG
cells, to produce cytokines and lyse the target cells. For example,
these high affinity scFvHyb3-  CD28POS T lymphocyte also
lysed MAGE-A1NEG melanoma cells, APD B-LCL, and K562 my-
eloid leukemia cells, albeit at lower levels (Fig. 4B). Like TCRs,
TCR-like Abs may display affinities for class I molecules present-
ing irrelevant peptides (25, 46). However, the rate of dissociation
FIGURE 4. ScFv receptors comprising   CD28
mediate a more potent cytolytic T cell response. Low
affinity ScFvG8-  CD28POS and scFvG8-POS pri-
mary human T lymphocytes (A) and high affinity
ScFvHyb3-  CD28POS and scFvHyb3-POS primary
human T lymphocytes (B) were incubated for 4 h, at
indicated effector to target cell ratios, with the follow-
ing 51Cr-labeled melanoma target cells: 1) A1/M1
MEL2.2; 2) MEL2.2  MAGE-A1 peptide (10 M
final); 3) A1/M1 MEL3.0; 4) A1/M1 K562; and
5) A1/M1 APD. ScFvG8-  CD28POS and scFv
Hyb3-POS T lymphocytes (C) mediate cytolysis with a
higher sensitivity to Ag density. ScFvG8-  CD28POS,
scFvG8-POS, scFvHyb3-POS and scFvHyb3- 
CD28POS primary human T lymphocytes were incubated
for 4 h, at indicated effector to target cell ratios, with 51Cr-
labeled MEL2.2 cells loaded with increasing concentra-
tions of MAGE-A1 peptide (M1, ranging from 0.01 to 10
M final concentration). Shown are mean percentages of
specific 51Cr release of triplicate measurements, with SDs
not exceeding 10% of mean values. Data from one repre-
sentative experiment (of three) are shown.
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of nonspecific TCR/MHC complexes is sufficiently high that dis-
sociation always occurs before the nonspecific interaction can ac-
tivate the TCR-expressing lymphocytes. The difference in disso-
ciation constant between Hyb3 and nonspecific HLA-A1
complexes vs Hyb3 and HLA-A1 molecules presenting
MAGE-A1 may be reduced when compared with the dissociation
constants of the G8 Ab/HLA-A1 complexes. The consequently
prolonged interaction of the Hyb3 receptor with the nonspecific
HLA-A1 in combination with the higher triggerable   CD28
signaling structure results in the “nonspecific” cytolysis and cyto-
kine production.
The affinity maturation of the TCR-like Ab scFvG8 allows the
generation of a library of CTL clones with a range of affinities
from low to high, based on the use of differential VHVL genes and
hence mimics the natural polymorphic T lymphocyte response.
The enhancement of the overall immune responses by either af-
finity maturation of the receptor, linkage of distinct signaling el-
ements together, or combinations thereof will produce T lympho-
cyte transductants that display distinct TRA triggerabilities: e.g.,
cytokine production levels and profiles; target cell lytic capacities;
and tumor mass penetration abilities. However, as shown here
maximum triggerability may result in loss of specificity of the
immune response and hence unwanted kill of innocent bystander
cells, thereby triggering autoimmune reactions. Therefore, it is
mandatory to test these T cell transductants for exquisite Ag spec-
ificity before use in clinical therapy protocols.
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